New drug targets hard-to-treat stomach and pancreatic cancers in early trial
NCT ID NCT07481357
First seen Mar 24, 2026 · Last updated Apr 28, 2026 · Updated 6 times
Summary
This early-phase study tests a new drug called DA-3501 in people with advanced stomach, gastro-esophageal junction, or pancreatic cancers that have a specific marker (CLDN18.2). The main goals are to find the safest dose and see if the drug can shrink tumors. About 51 adults will receive the drug once every three weeks and be closely monitored for side effects and cancer response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.